PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA

PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Placing of 50,000,000 New Ordinary Shares and Warrants
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
Poolbeg Pharma commences trading on OTCQB Market in the United States
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.
Sub-contract approach for VISITECT® COVID-19 antigen test